Back to all Current clinical trials
Back to all Current clinical trials
BGB-16673 - BTK-Degrader in combination for Relapsed or Refractory B-Cell Malignancies
First in human study looking at treating B-Cell malignancies with an oral drug that works with BTK inhibitors to improve their effectiveness even after failure to with prior treatment of BTK inhibitors.
What you need to know
Who can take part?
Main Inclusions
- B-Cell malignancies
- Measurable disease
- Life expectancy > 6 months
- Adequate organ function
- Main Exclusions
- treatment naive B-Cell malignancy
- Inability to comply with protocol
- Untreated brain metastasis
- Autologous stem cell transplant or CART < 3months
- active infections
What is involved for me?
- Oral treatment with 2 drugs.
- Weekly clinic visits for first 2 months then monthly for 3 then every 3 months.
- Regular PET/CT/MRI scans
